



Trial Information Summary

ALLG Trial Number:	AML20
Trial Name: A programme of development for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome	
Lay Summary: Many patients with acute myeloid leukaemia or high risk myelodysplastic syndrome are over the age of 60 years. Toxic treatments used in younger patients are often not suitable in older patients. Previous studies have shown that low dose Ara-C (LDAC) is a suitable treatment for this age group, but did not lead to long-term survival in most patients. This international study will compare new drugs to LDAC. The ALLG will participate in 2 arms of the study. The response of the disease following treatment and how long patients survive will be measured.	
Participating Hospitals: 1. Canberra / 2. Royal Darwin / 3. Royal Hobart / 4. Townsville	
Target Accrual (International):	n/a
Target Accrual (ALLG):	60
Expected Final Accrual Date:	June 2020